Xultophy
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies
December 5, 2017Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …
Novo’s Xultophy beats basal insulin in cutting cardiovascular risk
September 14, 2017Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
Sanofi and Novo to face off in diabetes sphere following FDA approvals
November 22, 2016Manufacturing and Production, Sales and Marketing FDA, Novo Nordisk, Sanofi, Soliqua, Xultophy, diabetes
Sanofi and Novo are set to face off in the diabetes market after the FDA approved combination treatments from the …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Latest content
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
